Aubagio is unlikely to reduce fatigue associated with Multiple Sclerosis (MS). 85% of patients with MS report fatigue and 76.6% report that fatigue has a significant impact on their lives. One study found ponesimod to be superior to Aubagio at reducing fatigue as measured by The Fatigue Symptoms and Impacts Questionnaire–Relapsing Multiple Sclerosis which is a patient-reported questionnaire designed to assess fatigue-related symptoms and how they affect people with MS. The investigators found that the fatigue of ponesimod patients stabilized, while that of the Aubagio patients worsened over time.